WEST LAFAYETTE, IN--(Marketwire - April 15, 2010) - Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today, as a result of having closing bid prices in excess of $1.00 per share for ten business days on the NASDAQ, that it is now in compliance with continued listing requirements of the NASDAQ Capital Market.
The Company had previously been informed by the NASDAQ Capital Market that it did not meet minimum bid price per share requirements. As a result of an increase in the market value of its stock, the Company is now in compliance with the Capital Market requirements.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASInc.com for more information about BASi.